Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults
Open Access
- 1 January 2018
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 75 (1) , 44-50
Abstract
Advances in understanding the pathophysiology of Alzheimer disease (AD), together with a US national plan to discover interventions to prevent AD by 2025, have led to clinical trials examining treatment in people at risk for development of the disease before they have disabling cognitive impairments.1 These trials enroll cognitively normal persons with evidence of AD biomarkers, including amyloid as measured by positron emission tomography (PET) or cerebrospinal fluid, often necessitating biomarker disclosure to participants.2 The amyloid imaging appropriate use criteria suggest that clinical disclosure is appropriate to aid the diagnosis of persons with dementia or mild cognitive impairment. However, the criteria do not recommend disclosure to cognitively normal adults,3 explaining that therapy for this group would change this recommendation. This explanation signals how biomarker disclosure to cognitively normal adults will be translated into clinical practice. There is no consensus, however, about whether and how to return AD biomarker results to cognitively normal adults given the prognostic uncertainty and absence of available treatments.4-7Keywords
This publication has 17 references indexed in Scilit:
- Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerabilityAlzheimer's & Dementia, 2015
- Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research ResultsJAMA Neurology, 2015
- Clinical use of amyloid‐positron emission tomography neuroimaging: Practical and bioethical considerationsAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2015
- Development of a process to disclose amyloid imaging results to cognitively normal older adult research participantsAlzheimer's Research & Therapy, 2015
- Effect of Knowledge of APOE Genotype on Subjective and Objective Memory Performance in Healthy Older AdultsAmerican Journal of Psychiatry, 2014
- Using AD biomarker research results for clinical careNeurology, 2013
- Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s AssociationJournal of Nuclear Medicine, 2013
- Addressing the ethical, policy, and social challenges of preclinical Alzheimer diseaseNeurology, 2011
- Disclosure of APOE Genotype for Risk of Alzheimer's DiseaseYearbook of Pediatrics, 2011
- Disclosure ofAPOEGenotype for Risk of Alzheimer's DiseaseNew England Journal of Medicine, 2009